Foreign reference pricing frameworks often differ from the way the US has historically valued medical innovation. A more ...
Perhaps the term “better” should not be defined by business metrics at all—but instead by the innovation’s health impacts ...
California cannot control whether mifepristone will remain available at the national level. But it can control whether ...
The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...
Congress should require the FDA to make DSCSA traceability data accessible and interpretable not only by regulatory agencies ...
Rather than impose one-size-fits-all solutions, federal and state policy makers should craft Medicaid payment policies that ...
In its current configuration, Food Is Medicine operates as a drain, not a fountain. Money flows into communities to pay for food and services, and grants are paid to support short-term projects, but ...
Having been stymied by courts elsewhere. the Justice Department has turned to a conservative federal district court in Texas ...
Exhibit 1 National health expenditures (NHE) and personal health care (PHC) expenditures, aggregate and per capita amounts, share of gross domestic product (GDP), and annual growth, selected calendar ...
Similar to opioids and intoxicating hemp-derived THC products, a well-funded and growing kratom industry with lobbying power ...
The Trump administration has proposed capping Medicaid state directed payments (SDPs) at 100 percent of Medicare rates in Medicaid expansion states and 110 percent of Medicare rat ...
Nasal naloxone remains expensive relative to the cost of the underlying drug and continues to strain budgets of public health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results